Jane Street Group LLC purchased a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,549 shares of the company's stock, valued at approximately $749,000. Jane Street Group LLC owned 0.08% of Upstream Bio at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the company. Moody Aldrich Partners LLC bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $1,229,000. Rhumbline Advisers bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $275,000. Bank of New York Mellon Corp bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $607,000. US Bancorp DE bought a new stake in shares of Upstream Bio in the fourth quarter valued at about $27,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Upstream Bio in the fourth quarter worth about $2,225,000.
Upstream Bio Stock Performance
NASDAQ:UPB traded down $0.40 during mid-day trading on Wednesday, hitting $9.22. The company's stock had a trading volume of 402,607 shares, compared to its average volume of 329,939. Upstream Bio, Inc. has a fifty-two week low of $5.14 and a fifty-two week high of $29.46. The stock has a fifty day moving average of $8.08 and a 200-day moving average of $12.13.
Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. Research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Stories
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
